Table 3

Selected characteristics of study participants at the time of NADC diagnosis
Lung cancer Hodgkin’s lymphoma Anal cancer Any NADC
Total number 140 (100.0) 112 (100.0) 79 (100.0) 880 (100.0)
Gender, n (%) Male 120 (85.7) 95 (84.8) 69 (87.3) 708 (80.5)
Female 20 (14.3) 17 (15.2) 10 (12.7) 173 (19.5)
Age (years) Median (IQR) 54 (47, 59) 43 (38, 50) 48 (44, 51) 50 (44, 59)
Mode of HIV acquisition, n (%) Men having sex with men 63 (45.0) 61 (54.5) 52 (65.8) 408 (46.4)
Injection drug user 25 (17.9) 15 (13.4) 15 (19.0) 153 (17.4)
Heterosexual 39 (27.9) 29 (25.9) 7 (8.9) 256 (29.1)
Other/unknown 13 (9.3) 7 (6.3) 5 (6.3) 63 (7.2)
Ethnic group, n (%) White 72 (51.4) 70 (62.5) 46 (58.2) 479 (54.4)
Black 1 (0.7) 4 (3.6) 1 (1.3) 27 (3.1)
Other 0 (-) 6 (5.4) 0 (-) 11 (1.3)
Unknown/not collected 67 (47.9) 32 (28.6) 32 (40.5) 363 (41.3)
BMI (kg/m2), n (%) <18 10 (7.1) 3 (2.7) 3 (3.8) 46 (5.2)
≥18, ≤26 64 (45.7) 69 (61.6) 48 (60.8) 439 (49.9)
>26, ≤30 9 (6.4) 17 (15.2) 5 (6.3) 79 (9.0)
>30 6 (4.3) 5 (4.5) 3 (3.8) 43 (4.9)
Unknown 51 (36.4) 25 (22.3) 20 (25.3) 273 (31.0)
CD4 count (cells/mm3) Median (IQR) 365 (230, 487) 274 (167, 451) 380 (253, 580) 392 (245, 580)
Nadir CD4 count (cells/m3) Median (IQR) 108 (53, 212) 134 (49, 232) 50 (16, 20) 127 (49, 245)
HIV RNA (log10 copies/ml) Median (IQR) 1.7 (1.7, 2.3) 1.7 (1.7, 3.8) 1.7 (1.7, 2.0) 1.7 (1.7, 2.4)
Prior NADC, n (%) 8 (5.7) 4 (3.6) 4 (5.1) 48 (5.5)
Prior ADC, n (%) 9 (6.4) 11 (9.9) 15 (19.0) 91 (10.3)
Year of diagnosis, n (%) 2004-2005 46 (32.9) 31 (27.7) 20 (25.3) 238 (27.0)
2006-2007 45 (32.1) 54 (48.2) 33 (41.7) 339 (38.5)
2008-2010 49 (35.0) 27 (24.1) 26 (32.9) 303 (34.4)
Smoking status, n (%) Current Smoker 71 (50.7) 45 (40.2) 40 (50.6) 386 (43.9)
Ex-smoker 55 (39.3) 30 (26.8) 22 (27.9) 253 (28.8)
Never smoked 3 (2.1) 21 (18.8) 9 (11.4) 136 (15.5)
Unknown 11 (7.9) 16 (14.3) 8 (10.1) 105 (11.9)
HCV positive, n (%) 11 (7.9) 5 (4.5) 8 (10.1) 75 (8.5)
HBV positive, n (%) 5 (3.6) 6 (5.4) 6 (7.6) 55 (6.3)
Any use of ARV, n (%) 130 (92.9) 99 (88.4) 78 (98.7) 813 (92.4)
Stage of disease, n (%) N 76 36 51 Not Collected
Localised 18 (23.7) 6 (16.7) 31 (60.8)
Disseminated 58 (76.3) 30 (83.3) 20 (39.2)

Worm et al.

Worm et al. BMC Infectious Diseases 2013 13:471   doi:10.1186/1471-2334-13-471

Open Data